OA12721A - Forme polymorphe du rimonabant, son procédé de préparation et les compositions pharmaceutiques en contenant. - Google Patents

Forme polymorphe du rimonabant, son procédé de préparation et les compositions pharmaceutiques en contenant. Download PDF

Info

Publication number: OA12721A
Authority: OA; OAPI
Prior art keywords: temperature; rimonabant; methylcyclohexane; medium; concentration
Prior art date: 2001-11-08

Application number

OA1200400131A

Other languages

English (en)

French (fr)

Inventor

Alain Alcade

Gilles Anne Archard

Corinne Gavory

Olivier Monnier

Original Assignee

Sanofi Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-08

Filing date

2002-11-04

Publication date

2006-06-27

2002-11-04 Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo

2006-06-27 Publication of OA12721A publication Critical patent/OA12721A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200400131A 2001-11-08 2002-11-04 Forme polymorphe du rimonabant, son procédé de préparation et les compositions pharmaceutiques en contenant. OA12721A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0114579A FR2831883B1 (fr)	2001-11-08	2001-11-08	Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number	Publication Date
OA12721A true OA12721A (fr)	2006-06-27

Family

ID=8869285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200400131A OA12721A (fr)	2001-11-08	2002-11-04	Forme polymorphe du rimonabant, son procédé de préparation et les compositions pharmaceutiques en contenant.

Country Status (33)

Country	Link
US (2)	US20050043356A1 (sr)
EP (1)	EP1446384A1 (sr)
JP (2)	JP4181994B2 (sr)
KR (2)	KR20050043774A (sr)
CN (1)	CN100412063C (sr)
AP (1)	AP1830A (sr)
AR (1)	AR037253A1 (sr)
AU (1)	AU2002350869B2 (sr)
BR (1)	BR0213931A (sr)
CA (1)	CA2464145A1 (sr)
CO (1)	CO5580827A2 (sr)
CR (1)	CR7333A (sr)
EA (1)	EA006771B1 (sr)
EC (1)	ECSP045088A (sr)
FR (1)	FR2831883B1 (sr)
GE (1)	GEP20063894B (sr)
HR (1)	HRP20040403A2 (sr)
HU (1)	HUP0402043A3 (sr)
IL (2)	IL161533A0 (sr)
IS (1)	IS7226A (sr)
MA (1)	MA27080A1 (sr)
ME (1)	MEP21908A (sr)
MX (1)	MXPA04004394A (sr)
NO (1)	NO326648B1 (sr)
NZ (1)	NZ532369A (sr)
OA (1)	OA12721A (sr)
PL (1)	PL369372A1 (sr)
RS (1)	RS36904A (sr)
TN (1)	TNSN04079A1 (sr)
TW (1)	TW200302824A (sr)
UA (1)	UA76776C2 (sr)
WO (1)	WO2003040105A1 (sr)
ZA (1)	ZA200402999B (sr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2831883B1 (fr) *	2001-11-08	2004-07-23	Sanofi Synthelabo	Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
KR101228376B1 (ko)	2002-07-18	2013-01-31	사이토스 바이오테크놀로지 아게	합텐-캐리어 컨쥬게이트 및 그의 용도
FR2861992B1 (fr) *	2003-11-10	2007-07-20	Sanofi Synthelabo	Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
NZ564759A (en)	2005-06-30	2011-08-26	Prosidion Ltd	GPCR agonists
EP1816125A1 (en) *	2006-02-02	2007-08-08	Ranbaxy Laboratories, Ltd.	Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
FR2897060B1 (fr) *	2006-02-08	2008-07-25	Sanofi Aventis Sa	Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
WO2008038143A2 (en) *	2006-06-22	2008-04-03	Medichem, S.A.	Novel solid forms of rimonabant and synthetic processes for their preparation
AR062593A1 (es) *	2006-08-29	2008-11-19	Medichem Sa	1-{[5-(4-clorofenil)-1-(2,4-diclorofenil)-4-metil-1h-pirazol-3-il]carbonil}-piperidina y proceso para preparar dicho compuesto; proceso para analizar la pureza de rimonabant,proceso para preparar rimonabant,rimonabant que se obtiene mediante dicho proceso y formulaciones.
EP2057144A4 (en) *	2006-09-01	2010-06-02	Hetero Drugs Ltd	NEW POLYMORPHIC FROM RIMONABANT
EP2061783A2 (en) *	2006-09-11	2009-05-27	Hetero Drugs Limited	Improved process for rimonabant
WO2008035023A1 (en) *	2006-09-19	2008-03-27	Cipla Limited	Polymorphs of rimonabant
WO2008056377A2 (en) *	2006-11-06	2008-05-15	Cadila Healthcare Limited	Polymorphic forms of rimonabant
WO2008064615A2 (en) *	2006-12-01	2008-06-05	Zentiva, A.S.	Crystalline and amorphous forms of rimonabant and processes for obtaining them
WO2008075013A1 (en) *	2006-12-18	2008-06-26	7Tm Pharma A/S	Modulators of cannabinoid receptor
BRPI0806498A2 (pt)	2007-01-04	2014-04-22	Prosidion Ltd	Agonistas gpcr piperidina
CL2008000018A1 (es)	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
AR064736A1 (es)	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
WO2008081208A1 (en)	2007-01-04	2008-07-10	Prosidion Limited	Piperidine gpcr agonists
EP1944297A1 (en) *	2007-01-09	2008-07-16	Miklós Vértessy	Solid and crystalline rimonabant and processes for preparation, and pharmaceutical composition thereof
WO2008088900A2 (en) *	2007-01-18	2008-07-24	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of rimonabant base and processes for preparation thereof
EP1953144A1 (en)	2007-01-30	2008-08-06	Sandoz AG	Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
FR2919864A1 (fr) *	2007-08-06	2009-02-13	Sanofi Aventis Sa	Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919867A1 (fr) *	2007-08-06	2009-02-13	Sanofi Aventis Sa	Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
FR2919865A1 (fr) *	2007-08-06	2009-02-13	Sanofi Aventis Sa	Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919862A1 (fr) *	2007-08-06	2009-02-13	Sanofi Aventis Sa	Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919863A1 (fr) *	2007-08-06	2009-02-13	Sanofi Aventis Sa	Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
WO2009153804A1 (en) *	2008-06-16	2009-12-23	Cadila Healthcare Limited	Process for preparing form i of rimonabant
WO2010079241A1 (es)	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
FR3008620A1 (fr) *	2013-07-22	2015-01-23	Sanofi Sa	Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
US12528771B2 (en)	2019-10-16	2026-01-20	Otsuka Pharmaceutical Co., Ltd.	Method for producing centanafadine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2692575B1 (fr) *	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) *	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.
WO2003015700A2 (en) *	2001-08-15	2003-02-27	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Novel vasoconstrictor cannabinoid analogs
FR2831883B1 (fr) *	2001-11-08	2004-07-23	Sanofi Synthelabo	Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

2001
- 2001-11-08 FR FR0114579A patent/FR2831883B1/fr not_active Expired - Fee Related
2002
- 2002-04-11 UA UA20040402974A patent/UA76776C2/uk unknown
- 2002-11-04 ME MEP-219/08A patent/MEP21908A/xx unknown
- 2002-11-04 CN CNB028219686A patent/CN100412063C/zh not_active Expired - Fee Related
- 2002-11-04 OA OA1200400131A patent/OA12721A/fr unknown
- 2002-11-04 GE GE5606A patent/GEP20063894B/en unknown
- 2002-11-04 AU AU2002350869A patent/AU2002350869B2/en not_active Ceased
- 2002-11-04 AP APAP/P/2004/003024A patent/AP1830A/en active
- 2002-11-04 CA CA002464145A patent/CA2464145A1/en not_active Abandoned
- 2002-11-04 WO PCT/FR2002/003765 patent/WO2003040105A1/fr not_active Ceased
- 2002-11-04 MX MXPA04004394A patent/MXPA04004394A/es unknown
- 2002-11-04 KR KR1020047006969A patent/KR20050043774A/ko not_active Abandoned
- 2002-11-04 RS YU36904A patent/RS36904A/sr unknown
- 2002-11-04 US US10/494,211 patent/US20050043356A1/en not_active Abandoned
- 2002-11-04 JP JP2003542151A patent/JP4181994B2/ja not_active Expired - Fee Related
- 2002-11-04 BR BR0213931-6A patent/BR0213931A/pt not_active IP Right Cessation
- 2002-11-04 EP EP02785580A patent/EP1446384A1/fr not_active Withdrawn
- 2002-11-04 PL PL02369372A patent/PL369372A1/xx not_active Application Discontinuation
- 2002-11-04 HR HR20040403A patent/HRP20040403A2/hr not_active Application Discontinuation
- 2002-11-04 NZ NZ532369A patent/NZ532369A/en not_active IP Right Cessation
- 2002-11-04 KR KR1020097016373A patent/KR20090089485A/ko not_active Ceased
- 2002-11-04 HU HU0402043A patent/HUP0402043A3/hu unknown
- 2002-11-04 EA EA200400491A patent/EA006771B1/ru not_active IP Right Cessation
- 2002-11-04 IL IL16153302A patent/IL161533A0/xx unknown
- 2002-11-06 AR ARP020104228A patent/AR037253A1/es unknown
- 2002-11-07 TW TW091132763A patent/TW200302824A/zh unknown
2004
- 2004-04-19 IS IS7226A patent/IS7226A/is unknown
- 2004-04-20 IL IL161533A patent/IL161533A/en not_active IP Right Cessation
- 2004-04-20 ZA ZA200402999A patent/ZA200402999B/en unknown
- 2004-04-27 EC EC2004005088A patent/ECSP045088A/es unknown
- 2004-04-28 MA MA27659A patent/MA27080A1/fr unknown
- 2004-05-04 CR CR7333A patent/CR7333A/es unknown
- 2004-05-04 CO CO04040840A patent/CO5580827A2/es not_active Application Discontinuation
- 2004-05-07 NO NO20041879A patent/NO326648B1/no not_active IP Right Cessation
- 2004-05-07 TN TNP2004000079A patent/TNSN04079A1/fr unknown
2008
- 2008-07-11 JP JP2008181474A patent/JP4931874B2/ja not_active Expired - Fee Related
- 2008-10-28 US US12/259,701 patent/US20100190827A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100190827A1 (en)	2010-07-29
RS36904A (sr)	2006-10-27
MEP21908A (en)	2010-06-10
MXPA04004394A (es)	2004-08-11
NZ532369A (en)	2005-10-28
HRP20040403A2 (en)	2004-08-31
CN1582278A (zh)	2005-02-16
HUP0402043A3 (en)	2009-07-28
JP2005508383A (ja)	2005-03-31
EP1446384A1 (fr)	2004-08-18
UA76776C2 (uk)	2006-09-15
HUP0402043A2 (hu)	2005-01-28
JP2009035547A (ja)	2009-02-19
MA27080A1 (fr)	2004-12-20
CO5580827A2 (es)	2005-11-30
AP2004003024A0 (en)	2004-06-30
FR2831883B1 (fr)	2004-07-23
WO2003040105A1 (fr)	2003-05-15
CA2464145A1 (en)	2003-05-15
KR20090089485A (ko)	2009-08-21
GEP20063894B (en)	2006-08-10
NO326648B1 (no)	2009-01-26
BR0213931A (pt)	2004-09-08
JP4181994B2 (ja)	2008-11-19
PL369372A1 (en)	2005-04-18
NO20041879L (no)	2004-06-08
AR037253A1 (es)	2004-11-03
CR7333A (es)	2008-09-23
EA006771B1 (ru)	2006-04-28
JP4931874B2 (ja)	2012-05-16
KR20050043774A (ko)	2005-05-11
TNSN04079A1 (fr)	2006-06-01
US20050043356A1 (en)	2005-02-24
AU2002350869B2 (en)	2007-07-26
ZA200402999B (en)	2005-04-20
ECSP045088A (es)	2004-06-28
TW200302824A (en)	2003-08-16
AP1830A (en)	2008-02-22
NO20041879D0 (no)	2004-05-07
IL161533A (en)	2010-05-31
FR2831883A1 (fr)	2003-05-09
CN100412063C (zh)	2008-08-20
IL161533A0 (en)	2004-09-27
EA200400491A1 (ru)	2004-12-30
IS7226A (is)	2004-04-19

Publication	Publication Date	Title
FR2831883A1 (fr)	2003-05-09	Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
EP0658546B1 (fr)	2001-05-23	Dérivés de 3-pyrazolecarboxamide avec une affinité pour le récepteur des cannabinoides
EP1230244B1 (fr)	2005-01-19	Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
EP1537087B1 (fr)	2012-11-28	Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant
EP0876350B1 (fr)	2001-07-11	Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0656354B1 (fr)	1997-06-04	N-pipéridino-3-pyrazolecarboxamide substitué
FR2779726A1 (fr)	1999-12-17	Forme polymorphe de l'hydrogenosulfate de clopidogrel
FR2815030A1 (fr)	2002-04-12	Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
WO2000046209A1 (fr)	2000-08-10	Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2792314A1 (fr)	2000-10-20	Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2569694A1 (fr)	1986-03-07	Derives d'ethylenediaminemonoamide, composition pharmaceutique les contenant et utilisation de ces composes a titre d'antidepresseur ou d'antiparkinsonien
JPH11502230A (ja)	1999-02-23	インダゾールカルボキサミド類
EP1102747B1 (fr)	2003-06-18	Formes cristallines du osanetant
CA2089349C (fr)	2001-10-16	Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2352563C2 (ru)	2009-04-20	Атропоизомеры производных 3-замещенного-4-арилхинолин-2-она
CA2557942C (fr)	2013-08-06	Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique
FR2897614A1 (fr)	2007-08-24	Forme cristalline du chlorhydrate de la besipirdine, procedes de preparation et utilisations
FR2897060A1 (fr)	2007-08-10	Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2845992A1 (fr)	2004-04-23	Derives de 3-(cyclopenten-1yl)-benzyl-ou3-(cyclopenten-1yl)- heteroarylmethyl-amines et leur utilisation a titre de medicaments pour le traitement de la schizophrenie
FR2789078A1 (fr)	2000-08-04	Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
WO2009053552A1 (fr)	2009-04-30	Le solvate de methanol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant.
FR2713224A1 (fr)	1995-06-09	N-pipéridino-3-pyrazolecarboxamide substitué.